Indications
·Type 2 diabetes(HbA1c≥7.0%)
·Adult obesity(BMI≥30 kg/m²)
Extended Indications
·Diabetes with atherosclerosis(carotid IMT reduction ≥ 0.1mm)
·Metabolic syndrome with hypertension(systolic BP reduc- tion≥5mmHg)
Features &Clinical Trial Data
1 Dual-Target Synergy:Concurrent activation of GLP-1/GIPreceptors,HbA1c reduction of 1.9%(vs.1.2%for single-tar-get agents).
2 Proprietary Delivery Technology:Bioavailability of 5%,peakplasma concentration achieved within 30 minutes post-dose.
3 PhaseⅢ Trial(n=2,158):
·24-week average weight loss:13.5kg(vs.2.1 kg in place- bo group).
·27%reduction in major cardiovascular event risk.
4 Safety Advantage:Incidence of severe hypoglycemia<0.3%(vs.4.7%in sulfonylurea group).
